ESTRO Brachytherapy for Prostate Cancer 2018

Prognostic ‘risk’ groups: Low – Intermediate - High

Depending on: -

Extension of the tumour

- -

Initial PSA

Gleason Score

Low Risk

Intermediate Risk

High Risk

Stage: T1 or T2a,b Gleason Sum < 6 PSA < 10 ng/ml

StageT1 or T1-2 StageT1-2 Gleason Score 7 or Gleason 6 PSA < 10 PSA 10-20

StageT2c or T3 Gleason score ≥ 8 PSA > 20 ng/mL